US 12,168,036 B2
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteinsGeneral
US 12,168,036 B2
Methods for treating angiogenic eye disorders with high doses of VEGF receptor fusion proteins
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Christine J Saoud
Art Unit:
1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Inventors:
Kenneth S. Graham; Kenneth S. Graham
Assignee:
Priority:
--
Filed:
07/23/21
Granted:
12/17/24
Expiration:
05/10/38
Cooperative Patent Classification (CPC)
A61A61K39/39591A61P27/02A61KC07K14/71C07K